在最新电话会议中，Cencora（COR）高管明确表示，公司的战略重心正锁定于视网膜与肿瘤两大治疗领域。他们强调，未来的并购活动将严格围绕“增值型补强式收购”展开。这种策略意在不偏离核心业务，通过精准补强，实现1+1>2的协同效应。高管们进一步阐释，此举旨在深化细分市场布局，而非盲目扩张。这一表态清晰勾勒出Cencora的资本配置路径，反映出其对专业赛道精耕细作的决心。
在最新电话会议中，Cencora（COR）高管明确表示，公司的战略重心正锁定于视网膜与肿瘤两大治疗领域。他们强调，未来的并购活动将严格围绕“增值型补强式收购”展开。这种策略意在不偏离核心业务，通过精准补强，实现1+1>2的协同效应。高管们进一步阐释，此举旨在深化细分市场布局，而非盲目扩张。这一表态清晰勾勒出Cencora的资本配置路径，反映出其对专业赛道精耕细作的决心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.